BioAge Labs, Inc. (NASDAQ:BIOA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

BioAge Labs, Inc. (NASDAQ:BIOA) has been given a consensus rating of “Moderate Buy” by the seven analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $43.50.

A number of equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Needham & Company LLC assumed coverage on shares of BioAge Labs in a research note on Friday, March 27th. They issued a “buy” rating and a $50.00 target price on the stock. Wall Street Zen lowered shares of BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Roth Capital initiated coverage on shares of BioAge Labs in a research note on Wednesday, May 27th. They set a “buy” rating and a $36.00 price target for the company. Finally, BTIG Research assumed coverage on BioAge Labs in a report on Wednesday, May 13th. They set a “buy” rating and a $40.00 price objective on the stock.

Institutional Trading of BioAge Labs

Several institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. bought a new stake in BioAge Labs in the third quarter valued at $27,000. CWM LLC lifted its holdings in shares of BioAge Labs by 39.9% during the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after acquiring an additional 1,053 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of BioAge Labs by 85.6% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after acquiring an additional 5,976 shares during the period. Walleye Capital LLC acquired a new stake in shares of BioAge Labs in the 2nd quarter valued at $64,000. Finally, Bank of America Corp DE boosted its stake in shares of BioAge Labs by 46.3% in the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after purchasing an additional 3,517 shares in the last quarter.

BioAge Labs Trading Up 2.9%

Shares of NASDAQ BIOA opened at $22.81 on Friday. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -9.50 and a beta of 0.61. BioAge Labs has a one year low of $4.11 and a one year high of $25.95. The business has a fifty day simple moving average of $19.88 and a 200 day simple moving average of $19.01.

BioAge Labs (NASDAQ:BIOA) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.19. The firm had revenue of $2.77 million for the quarter. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. On average, research analysts anticipate that BioAge Labs will post -2.68 earnings per share for the current fiscal year.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.